NL-OMON39089已完成4 期
Pneumonia treated with rifampicine attenuates inflammation - PRISTINE
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Patient aged 18 years or above
- •2. Community acquired pneumonia with CURB65 score >= 2;OR
- •1. Patient aged 18 years or above
- •hospitalized for community acquired pneumonia, and
- •clinical suspicion of pneumococcal pneumonia because of one or more of these features:
- •o pleuritic chest pain, or
- •o acute onset of symptoms, or
- •o cardiovascular disease in medical history, or
- •o leukocyte count > 15 x10e9/l (4), or
- •o on chest X-ray: an alveolar pattern (lobar, segmental or sub-segmental infiltrate) (5)
排除标准
- •Known allergy to rifampicin or anaemia or thrombopenia as side effect of rifampicin in medical history ;• Medication induced hepatitis or acute liver failure;• Porphyria;• Use of voriconazol or protease inhibitors ;• Female patients who are pregnant
研究者
相似试验
进行中（未招募）
不适用
rifampicine bij longontsteking vermindert de ontstekingsreactieEUCTR2012-003067-22-NLMC
已完成
不适用
Rifampicine vermindert de ontstekingsreactie bij patienten met een (matig) ernstige longontsteking.Community Acquired PneumoniaRifampicinLipoteichoid AcidPneumolysininflammatory responsclinical outcome prognosispneumoniaEmergency medicinehospitalSpoedeisende hulpziekenhuisThuis opgelopen longontstekingCURB-65 scorerifampicinelipoteichoidzuurpneumolysineinflammatoire responsprognoseklinische uitkomstpneumonieNL-OMON22991Prof. dr. J.T. van DisselLUMC40
已完成
不适用
A clinical trial to study the effect of Rifampicin in children with bacterial meningitisCTRI/2015/06/005951PGIMER40
进行中（未招募）
1 期
CLINICAL TRIAL TO EVALUATE THE EFFICIENCY OF PYRPHENIDONE FOR THE REDUCTION OF PULMONARY INFLAMMATION IN PATIENTS WITH SILICOSIS AND PROGRESSIVE MASSIVE FIBROSIS.progressive massive fibrosisMedDRA version: 20.0Level: PTClassification code 10040678Term: SilicosisSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 21.1Level: PTClassification code 10036805Term: Progressive massive fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-002701-94-ESFundación para la Gestión de la Investigación Biomédica de Cádiz18
进行中（未招募）
不适用
Effects of rifampicin on the pharmacokinetics and pharmacodynamics of sublingual and intravenous buprenorphineEUCTR2012-002871-32-FITurku University hospital